摘要
目的:评价螺内酯治疗顽固性高血压的疗效和安全性。方法:顽固性高血压患者随机分为观察组(58例)和对照组(66例),在常规三联抗高血压治疗的基础上观察组加用螺内酯20～40mg/d,对照组给予安慰剂,两组治疗均包括一种利尿剂,治疗第1周及1、3、6个月复查血钾、血肌酐、血压等。结果:螺内酯治疗1个月时显示出轻度的降压作用,以收缩压下降更为显著,随着疗程的延长,降压效果增强,治疗1、2、3个月两组收缩压(SBP)、舒张压(DBP)的变化值差异均有统计学意义(P均<0.05)。安全性方面,观察组血钾水平较对照组明显升高,治疗1、2、3个月两组血钾水平变化值差异均有统计学意义(P均<0.05)。治疗1、2、3个月观察组血肌酐水平有轻度上升,和对照组相比差异有统计学意义(P均<0.05),但均未超过正常上限。结论:螺内酯治疗顽固性高血压在严密监测下是有效的、安全的。
Objective： To evaluate the efficacy and safety of spironolactone on resistant hypertension（RH）.Methods： Patients with RH were enrolled and randomly divided into observation group（58 cases） and control group（66 cases） groups.Patients in observation group were treated with spironolactone,20-40 mg/d based on regular triple anti-hypertensive regimen,while those in the control group were given regular triple anti-hypertensive regimen plus placebo.All patients were treated with diuretics.Blood pressure,serum potassium and serum creatinine were checked the first week of treatment,1,3 and 6 months of treatment.Results： After 1 month of treatment,spironolactone showed slight depressurization,which gradually became obvious later.Changes in SBP and DBP were significant,after 1,2 and 3 months of treatment（P all 0.05）.Serum K＋ level of the observation group was significantly increased,significant difference in serum K＋ level was observed between the two groups after 1,2,3 months of treatment（P all 0.05）.But the creatinine level of the observation group slightly increased showing significant difference comparing with the control group although they were both in the normal rang（P all 0.05）.Conclusions： Spironolactone is effective and safe for patients with resistant hypertension under regular follow-up and close monitoring.
出处
《海南医学院学报》
CAS
2012年第6期788-790,793,共4页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210192)~~
关键词
螺内酯
顽固性高血压
临床试验
Spironolactone
Resistant hypertension
Clinical trial
